MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
8.16%
Quick Ratio
8.16%
Debt to Asset Ratio
33.26%
Unit: Dollar
Assets Breakdown
Investment in gmp bio at fair va...
Goodwill, net of impairment
Investment in equity securities
Others
Liabilities Breakdown
Accumulated equity
Deferred income tax liability
Additional paid-in capital
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash
186,014
63,614
88,857
409,000
Restricted cash
20,000
20,000
20,000
20,000
Accounts receivable
2,058
2,058
51,324
3,976
Prepaid & other current assets
-
-
-
1,179,972
Prepaid and other current assets
1,252,670
1,979,377
1,038,071
-
Total current assets
1,460,742
2,065,049
1,198,252
1,612,948
In process r&d
1,101,760
1,101,760
1,101,760
1,101,760
Goodwill, net of impairment
2,788,230
2,788,230
2,788,230
2,788,230
Investment in equity securities
1,400,000
-
-
-
Investment in gmp bio at fair value
388,000,000
388,000,000
388,000,000
22,653,225
Total assets
394,750,732
393,955,039
393,088,242
28,156,163
Accounts payable and accrued liabilities
2,554,999
2,470,889
2,571,123
2,565,877
Accounts payable to related party-Related Party
349,138
348,625
348,111
347,598
Contingent consideration
2,625,000
2,625,000
2,625,000
2,625,000
Derivative liability on notes
337,256
440,124
350,044
670,844
Convertible debt and short-term debt, net of costs-Nonrelated Party
7,925,881
8,246,199
8,225,669
10,328,100
Convertible debt and short-term debt, net of costs-Related Party
4,114,684
4,273,152
4,023,331
3,542,244
Total current liabilities
17,906,958
18,403,989
18,143,278
20,079,663
Convertible debt
-
-
1,663,405
-
Convertible long-term debt, net of costs
1,854,395
1,789,509
-
-
Deferred income tax liability
111,550,000
111,550,000
111,550,000
-
Total liabilities
131,311,353
131,743,498
131,356,683
20,079,663
Convertible preferred stock, 0.01 par value, 15,000,000 shares authorized 50,900 and 24,388 issued and outstanding, respectively
509
509
244
-
Common stock, 0.01 par value 750,000,000 shares authorized 457,012,796 and 442,596,856 issued and outstanding, respectively
4,570,125
4,441,970
4,425,968
4,394,463
Additional paid-in capital
50,556,882
49,798,210
47,095,219
43,765,008
Accumulated equity
209,433,535
209,045,388
211,239,164
-39,108,893
Total oncotelic therapeutics, inc. stockholders equity
264,561,051
263,286,077
262,760,595
9,050,578
Non-controlling interests
-1,121,672
-1,074,536
-1,029,036
-974,078
Total stockholders equity
263,439,379
262,211,541
261,731,559
8,076,500
Total liabilities and stockholders equity
394,750,732
393,955,039
393,088,242
28,156,163
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Prepaid and other
current assets
$1,252,670
Cash
$186,014
(111.33%↑ Y/Y)
Restricted cash
$20,000
(0.00%↑ Y/Y)
Accounts receivable
$2,058
(-89.15%↓ Y/Y)
Investment in gmp bio at fair
value
$388,000,000
(1612.78%↑ Y/Y)
Goodwill, net of
impairment
$2,788,230
(0.00%↑ Y/Y)
Total current assets
$1,460,742
(961.65%↑ Y/Y)
Investment in equity
securities
$1,400,000
In process r&d
$1,101,760
(0.00%↑ Y/Y)
Total assets
$394,750,732
(1379.53%↑ Y/Y)
Total liabilities and
stockholders equity
$394,750,732
(1379.53%↑ Y/Y)
Total stockholders
equity
$263,439,379
(3462.93%↑ Y/Y)
Total liabilities
$131,311,353
(580.83%↑ Y/Y)
Non-controlling interests
-$1,121,672
(-23.66%↓ Y/Y)
Total oncotelic
therapeutics, inc....
$264,561,051
(3087.11%↑ Y/Y)
Deferred income tax
liability
$111,550,000
Total current
liabilities
$17,906,958
(-7.15%↓ Y/Y)
Convertible long-term debt,
net of costs
$1,854,395
Accumulated equity
$209,433,535
(650.25%↑ Y/Y)
Additional paid-in capital
$50,556,882
(19.58%↑ Y/Y)
Common stock, 0.01 par
value 750,000,000...
$4,570,125
(11.93%↑ Y/Y)
Convertible preferred
stock, 0.01 par value,...
$509
Convertible debt and
short-term debt, net of...
$7,925,881
Convertible debt and
short-term debt, net of...
$4,114,684
Contingent consideration
$2,625,000
(0.00%↑ Y/Y)
Accounts payable and
accrued liabilities
$2,554,999
(2.72%↑ Y/Y)
Accounts payable to
related party-Related...
$349,138
(0.59%↑ Y/Y)
Derivative liability on
notes
$337,256
(20.97%↑ Y/Y)
Buy us a coffee
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)